AbbVie Inc. (NYSE:ABBV) is a top long-term low volatility stock to buy now. Morgan Stanley analyst Terrence Flynn reiterated a Buy rating with a price target of $250. Positive Q1 2025 results show growth in adjusted diluted EPS by 6.5% to $2.46 and $13.343 billion in net revenue, up 8.4% reported or 9.8% operational. AbbVie is a research-based pharmaceutical company specializing in chronic disease treatments across various sectors. While AbbVie is a solid investment, consider AI stocks for greater upside potential. No disclosures.

Read more at Yahoo Finance: Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT